Invention Grant
- Patent Title: 5-alkyl pyrrolidine orexin receptor agonists
-
Application No.: US16787201Application Date: 2020-02-11
-
Publication No.: US11098029B2Publication Date: 2021-08-24
- Inventor: Stephane L. Bogen , Dane James Clausen , Deodial Guy Guiadeen , Michael T. Rudd , Dexi Yang
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Dianne Pecoraro; John C. Todaro
- Main IPC: C07D401/14
- IPC: C07D401/14 ; C07D207/16 ; C07D403/12 ; C07D409/12
Abstract:
The present invention is directed to 5-alkyl pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
Public/Granted literature
- US20200255403A1 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS Public/Granted day:2020-08-13
Information query
